AR083367A1 - Compuestos de tipo quinazolinona como antagonistas de crth - Google Patents

Compuestos de tipo quinazolinona como antagonistas de crth

Info

Publication number
AR083367A1
AR083367A1 ARP110103734A ARP110103734A AR083367A1 AR 083367 A1 AR083367 A1 AR 083367A1 AR P110103734 A ARP110103734 A AR P110103734A AR P110103734 A ARP110103734 A AR P110103734A AR 083367 A1 AR083367 A1 AR 083367A1
Authority
AR
Argentina
Prior art keywords
alkyl
aryl
heteroaryl
cycloalkyl
heterocyclyl
Prior art date
Application number
ARP110103734A
Other languages
English (en)
Original Assignee
Schering Corp
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp, Merck Sharp & Dohme filed Critical Schering Corp
Publication of AR083367A1 publication Critical patent/AR083367A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines having two or more nitrogen atoms in the same ring, e.g. oxadiazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems

Abstract

Compuestos, composición farmacéutica, así como procesos para preparar estos compuestos. Son útiles en el tratamiento de trastornos de tipo alérgicos inmunes tanto crónicos como agudos.Reivindicación 1: Un compuesto para la fórmula (1) o una sal farmacéuticamente aceptable del mismo, en la que: X es un enlace o -S(O)m-; Y se selecciona entre el grupo que consiste en: a) un enlace, -O-, -NH-, -N(R9)- o -N(COR9)-; b) un resto de fórmulas (2); c) un resto de fórmulas (3); d) un resto de fórmulas (4); y e) un resto de fórmulas (5); en las que A es -O-, -S- o -N(R)-; B es -C-, -N-; a es 0, 1, 2 ó 3; r es 0, 1 ó 2; s es 0, 1 ó 2; R es H, alquilo o haloalquilo; Ra es independientemente H, halo, alquilo o haloalquilo; Rb es independientemente H, halo, alquilo o haloalquilo; R1 es heteroarilo, heterociclilo o heterociclenilo; R2 es arilo, heteroarilo, alquilo o heterociclilo; R3 es -C(O)OH o -N(H)-SO2-Rc; en las que Rc es alquilo, haloalquilo, cicloalquilo, arilo o heteroarilo; R4 se selecciona independientemente entre el grupo que consiste en alquilo, -OH, halo, alcoxi, haloalcoxi, -CN y haloalquilo; R8 se selecciona independientemente entre el grupo que consiste en -CN, halo, alquilo, haloalquilo, alcoxi, haloalcoxi o cicloalquilo; R9 es alquilo, haloalquilo, alcoxi, haloalcoxi o cicloalquilo; y en la que: i) el grupo heteroarilo, heterociclilo o heterociclenilo en R1; y ii) cada uno de los grupos arilo, heteroarilo, alquilo o heterociclilo de R2; están sin sustituir o sustituidos independientemente con 1 a 5 grupos R5 seleccionados independientemente entre el grupo que consiste en alquilo, alquenilo, alquinilo, cicloalquilo, cicloalquenilo, heterociclilo, heterociclenilo, arilo, heteroarilo, halo, -CN, -SF5, -OSF5, -NO2, -CH2OSi(R14)(R15)(R16), -OR14, -C(O)R14, -C(O)OR14, -O-C(O)-R14, -O-C(O)N(R14)(R15), -C(O)N(R14)(R15), -S(O)mR14, -S(O)pN(R14)(R15), - C(=NOR14)R15, -N(R14)(R15), -N(R14)C(O)R15, -N(R14)S(O)pR15, -N(R14)S(O)pN(R15)(R16), -N(R14)C(O)N(R15)(R16) y -N(R14)C(O)OR16; o cuando una posición esta disustituida con dos grupos R5, los dos grupos R5 pueden formar un anillo de cicloalquilo o heterociclilo que está sin sustituir o está sustituido con 1 a 5 grupos R6 y en la que cada uno de los grupos alquilo, alquenilo, alquinilo, cicloalquilo, cicloalquenilo, heterociclilo, heterociclenilo, arilo, heteroarilo en R5 están sin sustituir o sustituidos independientemente con 1 a 5 grupos R6 seleccionados independientemente entre el grupo que consiste en alquilo, alquenilo, alquinilo, cicloalquilo, cicloalquenilo, heterociclilo, heterociclenilo, arilo, heteroarilo, halo, -CN, -SF5, -OSF5, -NO2, -CH2OSi(R14)(R15)(R16), -OR14, -C(O)R14, -C(O)OR14, -O-C(O)-R14, -O-C(O)N(R14)(R15), -C(O)N(R14)(R15), -S(O)mR14, -S(O)pN(R14)(R15), -C(=NOR14)R15, -N(R14)(R15), -N(R14)C(O)R15, -N(R14)S(O)pR15, -N(R14)S(O)pN(R15)(R16), -N(R14)C(O)N(R15)(R16) y -N(R14)C(O)OR16; y en la que cada uno de los grupos alquilo, alquenilo alquinilo, cicloalquilo, cicloalquenilo, heterociclilo, heterociclenilo, arilo, heteroarilo en R6 están sin sustituir o sustituidos independientemente con 1 a 5 grupos R7 seleccionados independientemente entre el grupo que consiste en alquilo, alquenilo, alquinilo, cicloalquilo, cicloalquenilo, heterociclilo, heterociclenilo, arilo, heteroarilo, halo, -CN, -SF5, -OSF5, -NO2, -CH2OSi(R14)(R15)(R16), -OR14, -C(O)R14, -C(O)OR14, -O-C(O)-R14, -O-C(O)N(R14)(R15), -C(O)N(R14)(R15), -S(O)mR14, -S(O)pN(R14)(R15), -C(=NOR14)R15, -N(R14)(R15), -N(R14)C(O)R15, -N(R14)S(O)pR15, -N(R14)S(O)pN(R15)(R16), -N(R14)C(O)N(R15)(R16) y -N(R14)C(O)OR16; en la que R14, R15 y R16 se seleccionan independientemente entre el grupo que consiste en H, alquilo, alquenilo, alquinilo, cicloalquilo, cicloalquenilo, heterociclilo, heterociclenilo, arilo, heteroarilo, R17-alquilo, R17-alquenilo, R17-alquinilo, R17-cicloalquilo, R17-cicloalquenilo, R17-heterociclilo, R17-heterociclenilo, R17-arilo y R17-heteroarilo; R17 es 1 - 5 sustituyentes seleccionados independientemente entre el grupo que consiste en alquilo, alquenilo, alquinilo, cicloalquilo, cicloalquenilo, heterociclilo, heterociclenilo, arilo, arilo sustituido con halo, arilo sustituido con nitrilo, arilo sustituido con fenilo, heteroarilo, halo, -CN, -SF5, -OSF5, -NO2, heteroarilo, haloalquilo, -C(O)R18, -C(O)OH, -C(O)OR18, -C(O)NHR19, -C(O)NH2, -C(O)N(R18)(R19), -S(O)mR18, -S(O)pNH2, -S(O)pNH(alquilo), -S(O)pN(alquil)(alquilo), -S(O)pNH(arilo), -S(O)2NHR19, -S(O)2NH(heterocicloalquilo), -S(O)2N(alquil)(arilo), haloalcoxi, -OH, -OR19, -O-heterocicloalquilo, -O-cicloalquilalquilo, -O-heterociclilalquilo, -NH2, -NHR19, -N(alquilo)2, -N(arilalquilo)2, -N(arilalquil)-(heteroarilalquilo), -NHC(O)R19, -NHC(O)NH2, -NHC(O)NH(alquilo), -NHC(O)N(alquil)(alquilo), -N(alquil)C(O)NH(alquilo), -N(alquil)C(O)N(alquil)(alquilo), -NHS(O)2R21, -NHS(O)2NH(alquilo), -NHS(O)2N(alquil)(alquilo), -N(alquil)S(O)2NH(alquilo) y -N(alquil)S(O)2N(alquil)(alquilo); R18 es alquilo, cicloalquilo, arilo, arilalquilo o heteroarilalquilo; R19 es alquilo, cicloalquilo, arilo, arilo sustituido con halo, arilalquilo, heteroarilo o heteroarilalquilo; R21 es alquilo, cicloalquilo, arilo, arilo sustituido con halo, arilalquilo, heteroarilo o heteroarilalquilo; b es 0, 1 ó 2, n es un número entero de 1 a 5; m es independientemente un número entero de 0 a 2; p es un número entero de 1 a 2; y q es un número entero de 0 a 5.
ARP110103734A 2010-10-11 2011-10-11 Compuestos de tipo quinazolinona como antagonistas de crth AR083367A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US39186410P 2010-10-11 2010-10-11

Publications (1)

Publication Number Publication Date
AR083367A1 true AR083367A1 (es) 2013-02-21

Family

ID=45938659

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP110103734A AR083367A1 (es) 2010-10-11 2011-10-11 Compuestos de tipo quinazolinona como antagonistas de crth

Country Status (5)

Country Link
US (1) US8927559B2 (es)
EP (1) EP2627178B1 (es)
AR (1) AR083367A1 (es)
TW (1) TW201305135A (es)
WO (1) WO2012051036A1 (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9469615B2 (en) 2010-12-23 2016-10-18 Merck Sharp & Dohme Corp. Quinoxalines and AZA-quinoxalines as CRTH2 receptor modulators
EP2661265B1 (en) 2010-12-23 2017-03-08 Merck Sharp & Dohme Corp. Quinolines and aza-quinolines as crth2 receptor modulators
US8592383B2 (en) 2011-06-17 2013-11-26 Merck Sharp & Dohme Corp. Cycloalkyl-fused tetrahydroquinolines as CRTH2 receptor modulators
US8809372B2 (en) 2011-09-30 2014-08-19 Asana Biosciences, Llc Pyridine derivatives
EP2760833A1 (en) * 2011-09-30 2014-08-06 Endo Pharmaceuticals Inc. Pyridine derivatives
GEP20166554B (en) 2012-04-25 2016-10-10 Takeda Pharmaceuticals Co Nitrogenated heterocyclic compound
EP2873669A4 (en) 2012-07-13 2015-11-25 Takeda Pharmaceutical HETEROCYCLIC COMPOUND
WO2014055311A1 (en) 2012-10-01 2014-04-10 Merck Sharp & Dohme Corp. Substituted isoquinolines as crth2 receptor modulators
EP2746256A1 (en) 2012-12-19 2014-06-25 Basf Se Fungicidal imidazolyl and triazolyl compounds
WO2014095249A1 (en) 2012-12-19 2014-06-26 Basf Se Fungicidal imidazolyl and triazolyl compounds
EP2746257A1 (en) 2012-12-21 2014-06-25 Basf Se Substituted [1,2,4]triazole and imidazole compounds
EP2746258A1 (en) 2012-12-21 2014-06-25 Basf Se Substituted [1,2,4]triazole and imidazole compounds
EP2746259A1 (en) 2012-12-21 2014-06-25 Basf Se Substituted [1,2,4]triazole and imidazole compounds
EP2746260A1 (en) 2012-12-21 2014-06-25 Basf Se Substituted [1,2,4]triazole and imidazole compounds
JP6280912B2 (ja) 2013-03-14 2018-02-14 武田薬品工業株式会社 複素環化合物
ES2950424T3 (es) 2013-07-03 2023-10-09 Takeda Pharmaceuticals Co Compuesto de amida
JP6427491B2 (ja) 2013-07-03 2018-11-21 武田薬品工業株式会社 複素環化合物
EP3325464B1 (en) 2015-07-24 2022-04-20 Basf Se Pyridine compounds useful for combating phytopathogenic fungi
US20170050980A1 (en) * 2015-08-18 2017-02-23 Forum Pharmaceuticals Inc. Oxadiazine compounds and methods of use thereof
EA201890627A3 (ru) 2015-09-03 2021-11-30 Басф Агро Б.В. Гербицидная композиция микрочастиц, включающая сафлуфенацил, способ ее получения и ее применение
BR112018006314A2 (pt) 2015-10-05 2018-10-16 Basf Se composto da fórmula, composição, uso de composto da fórmula, método de combate a fungos fitopatogênicos e semente revestida
WO2018054711A1 (en) 2016-09-26 2018-03-29 Basf Se Pyridine compounds for controlling phytopathogenic harmful fungi
WO2018054723A1 (en) 2016-09-26 2018-03-29 Basf Se Pyridine compounds for controlling phytopathogenic harmful fungi
WO2018054721A1 (en) 2016-09-26 2018-03-29 Basf Se Pyridine compounds for controlling phytopathogenic harmful fungi
WO2018065182A1 (en) 2016-10-04 2018-04-12 Basf Se Reduced quinoline compounds as antifuni agents
WO2018073110A1 (en) 2016-10-20 2018-04-26 Basf Se Quinoline compounds as fungicides
CN110191881A (zh) 2017-01-23 2019-08-30 巴斯夫欧洲公司 杀真菌的吡啶化合物
EP3606914A1 (en) 2017-04-06 2020-02-12 Basf Se Pyridine compounds
CN107033135B (zh) 2017-05-26 2020-09-11 浙江省诸暨合力化学对外贸易有限公司 一种制备异噁嗪酮化合物的方法及其应用
WO2019115343A1 (en) 2017-12-15 2019-06-20 Basf Se Fungicidal mixture comprising substituted pyridines
US11760701B2 (en) 2018-02-27 2023-09-19 The Research Foundation For The State University Of New Yrok Difluoromethoxylation and trifluoromethoxylation compositions and methods for synthesizing same
JP6994061B2 (ja) 2019-02-15 2022-01-14 ノバルティス アーゲー ４－（７－ヒドロキシ－２－イソプロピル－４－オキソ－４ｈ－キナゾリン－３－イル）－ベンゾニトリルの製剤
CA3130038A1 (en) 2019-02-15 2020-08-20 Novartis Ag Methods for treating ocular surface pain
US11787796B2 (en) 2019-09-18 2023-10-17 Takeda Pharmaceutical Company Limited Plasma Kallikrein inhibitors and uses thereof
WO2022197756A1 (en) * 2021-03-17 2022-09-22 Shire Human Genetic Therapies, Inc. Plasma kallikrein inhibitors

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4183931A (en) 1977-09-08 1980-01-15 Research Corporation 2-Ketoalkyl-4(3H)-quinazolinones
NZ194883A (en) 1979-10-02 1983-05-31 Ici Australia Ltd -(quinoxalin-2-ylaminophen (oxy or ylthio) alkanoic acid derivatives
AU693143B2 (en) 1993-12-06 1998-06-25 Cytel Corporation CS-1 peptidomimetics, compositions and methods of using the same
US5510332A (en) 1994-07-07 1996-04-23 Texas Biotechnology Corporation Process to inhibit binding of the integrin α4 62 1 to VCAM-1 or fibronectin and linear peptides therefor
DE69530392D1 (de) 1994-07-11 2003-05-22 Athena Neurosciences Inc Inhibitoren der leukozytenadhäsion
US5811391A (en) 1994-08-25 1998-09-22 Cytel Corporation Cyclic CS-1 peptidomimetics, compositions and methods of using same
GB9524630D0 (en) 1994-12-24 1996-01-31 Zeneca Ltd Chemical compounds
US6306840B1 (en) 1995-01-23 2001-10-23 Biogen, Inc. Cell adhesion inhibitors
WO1996031206A2 (en) 1995-04-07 1996-10-10 Warner-Lambert Company Flavones and coumarins as agents for the treatment of atherosclerosis
WO1996040781A1 (en) 1995-06-07 1996-12-19 Tanabe Seiyaku Co., Ltd. CYCLIC PEPTIDE INHIBITORS OF β1 AND β2 INTEGRIN-MEDIATED ADHESION
KR19990028709A (ko) 1995-07-05 1999-04-15 미리암 디. 메코너헤이 살진균 피리미디논
EP0842195A1 (en) 1995-07-06 1998-05-20 Zeneca Limited Peptide inhibitors of fibronectine
US6248713B1 (en) 1995-07-11 2001-06-19 Biogen, Inc. Cell adhesion inhibitors
BR9714222A (pt) 1996-12-17 2000-04-18 Du Pont Método para o controle de doenças de plantas
US6255311B1 (en) 1998-01-14 2001-07-03 E. I. Du Pont De Nemours And Company Fungicidal fused bicyclic pyrimidinones
US6518407B1 (en) 1999-04-01 2003-02-11 The Procter & Gamble Company Reactive dye compound comprising at least one chromophore moiety and at least one nitrogen-containing heterocycle
US6545004B1 (en) * 1999-10-27 2003-04-08 Cytokinetics, Inc. Methods and compositions utilizing quinazolinones
FR2827206B1 (fr) 2001-07-10 2004-04-02 Nature Bois Emballages Procede et dispositif de formage de planchettes, et emballages comportant de telles planchettes
BR0312802A (pt) 2002-07-19 2005-04-19 Michael E Garst Pró-drogas de inibidores de bombas de próton
EP1398032A1 (en) 2002-09-10 2004-03-17 PheneX Pharmaceuticals AG 4-Oxo-quinazolines as LXR nuclear receptor binding compounds
WO2004111014A1 (en) 2003-06-06 2004-12-23 Vertex Pharmaceuticals Incorporated Pyrimidine derivatives as modulators of atp-binding cassette transporters
KR20060041224A (ko) 2003-07-15 2006-05-11 알러간, 인코포레이티드 양성자 펌프 억제제의 이성질체적으로 순수한 프로드러그를제조하는 방법
GB0324763D0 (en) 2003-10-23 2003-11-26 Oxagen Ltd Use of compounds in therapy
US20070135454A1 (en) 2003-11-14 2007-06-14 Tracy Bayliss Bicyclic pyrimidin-4(3h)-ones and analogues and derivatives thereof which modulate the function of the vanilloid-1-receptor(vr1)
DK1718649T3 (da) 2004-01-31 2009-08-24 Actimis Pharmaceuticals Inc Imidazo[1,2-c]pyrimidinyleddikesyrederivater
WO2005079803A1 (en) 2004-02-13 2005-09-01 Pfizer Products, Inc. Compounds for treatment of cardiovascular diseases
BRPI0519280A2 (pt) 2004-12-27 2009-01-06 Actelion Pharmaceuticals Ltd composto, composiÇço farmacÊutica e uso de um composto
JP2009536608A (ja) 2005-05-11 2009-10-15 メルク シャープ エンド ドーム リミテッド バニロイド−１受容体（ｖｒ１）の機能を調節する２，３−置換縮合二環式ピリミジン４−（３ｈ）−オン
GB0605743D0 (en) 2006-03-22 2006-05-03 Oxagen Ltd Salts with CRTH2 antagonist activity
US20100093738A1 (en) 2006-10-06 2010-04-15 Basf Se Fungicidal Compounds and Fungicidal Compositions
CA2680783C (en) 2007-03-23 2012-04-24 Amgen Inc. Heterocyclic compounds and their uses
US20090054468A1 (en) 2007-08-23 2009-02-26 Astrazeneca Ab New Use 938
WO2011060394A1 (en) 2009-11-16 2011-05-19 Schering Corporation Compounds useful as chemokine receptor antagonists
WO2011060395A1 (en) 2009-11-16 2011-05-19 Schering Corporation Cyclic ureas useful as hiv inhibitors
US9469615B2 (en) 2010-12-23 2016-10-18 Merck Sharp & Dohme Corp. Quinoxalines and AZA-quinoxalines as CRTH2 receptor modulators
EP2661265B1 (en) 2010-12-23 2017-03-08 Merck Sharp & Dohme Corp. Quinolines and aza-quinolines as crth2 receptor modulators

Also Published As

Publication number Publication date
EP2627178A4 (en) 2014-08-20
US8927559B2 (en) 2015-01-06
EP2627178A1 (en) 2013-08-21
TW201305135A (zh) 2013-02-01
EP2627178B1 (en) 2018-05-02
US20130210805A1 (en) 2013-08-15
WO2012051036A1 (en) 2012-04-19

Similar Documents

Publication Publication Date Title
AR083367A1 (es) Compuestos de tipo quinazolinona como antagonistas de crth
AR082889A1 (es) Compuestos y composiciones para la inhibicion de nampt
PE20140863A1 (es) Compuestos de benceno sustituidos con arilo o heteroarilo
PE20171341A1 (es) Compuestos de pirazina para el tratamiento de enfermedades infecciosas
ES2626555T3 (es) Pyridone amides como moduladores de canales de sodio
AR043508A1 (es) 1-amino 1-h-imidazoquinolinas y su uso como inmunomoduladores
ES2556350T3 (es) Inhibidores de indazol de la vía de señalización de Wnt y sus usos terapéuticos
AR086983A1 (es) Derivados de azetidinil fenil, piridil o pirazinil carboxamida como inhibidores de jak
AR049300A1 (es) Compuestos triciclicos antagonistas de mglur1 como agentes terapeuticos
AR092108A1 (es) Piridazina 1,4 disustituida, analogos de la misma y metodos para tratar las enfermedades relacionadas con deficiencia del smn
AR050952A1 (es) Derivados de indazolona; procesos para su obtencion; composiciones farmaceuticas que los contienen y su uso en la fabricacion de medicamentos para el tratamiento de enfermedades mediadas por la inhibicion de la enzima 11beta - hsd1.
AR036492A1 (es) Inhibidores de la 17beta-hidroxiesteroide deshidrogenasa tipo 3, composiciones farmaceuticas y el uso de dichos inhibidores para la elaboracion de un medicamento para el tratamiento de enfermedades androgeno dependientes
AR077267A1 (es) Derivados nitrogenados heterociclicos inhibidores selectivos de pi3k, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de enfermedades inflamatorias y/o autoinmunes.
AR083199A1 (es) Compuestos de n-heteroarilo con unidad de puente ciclico
AR054560A1 (es) Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer
PE20090042A1 (es) Analogos de ciclopamina
AR078542A1 (es) Moduladores de gpr40 de pirrolidina
AR048939A1 (es) Derivados de fenol y tiofenol 3 - o 4 - monosustituidos utiles como ligandos de h3; composiciones farmaceuticas que los contienen y su uso en la fabricacion de medicamentos para el tratamiento de trastornos neurologicos e inflamatorios.
AR078786A1 (es) Derivados de la cromenona
UY29312A1 (es) Piperazin-1-carboxamidas n,4,sustituidas y sus derivados, composiciones que los contienen, procedimientos de preparación y aplicaciones
PE20141598A1 (es) Derivados de dihidro-benzo-oxazina y dihidro-pirido-oxazina
PE20141352A1 (es) Fenil-3-aza-biciclo[3,1,0]hex-3-il-metanonas y su uso como medicamento
AR059886A1 (es) Derivados de amidas como inhibidores de renina
CO2019004978A2 (es) Compuestos terapéuticos y métodos para utilizarlos
AR082111A1 (es) Furopiridinas o tienopiridinas condensadas, composiciones farmaceuticas que las contienen utiles para tratar trastornos psicoticos y del sistema nervioso central, y metodo de preparacion de las mismas

Legal Events

Date Code Title Description
FA Abandonment or withdrawal